Biomarkers do not paint the whole picture: The role of clinical expertise and advanced neuroimaging for Alzheimer's disease diagnosis.

Hadrien M Lalive, Alessandra Griffa, Lorenzo Pini, Olivier Rouaud, Gilles Allali

Abstract read

In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hadrien M LaliveDepartment of Clinical Neurosciences, Leenaards Memory Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0009-8677-0236

Alessandra GriffaDepartment of Clinical Neurosciences, Leenaards Memory Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1923-1653

Lorenzo PiniDepartment of Neuroscience, University of Padova, Padova, Italy.ORCID 0000-0002-9305-3376

Olivier RouaudDepartment of Clinical Neurosciences, Leenaards Memory Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-9767-8421

Gilles AllaliDepartment of Clinical Neurosciences, Leenaards Memory Center, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-4455-6719

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate diagnosis of Alzheimer's disease (AD) in Memory Clinics remains challenging due to the limited specificity of conventional clinical assessment and structural imaging. The recent commentary by Vyhnalek and colleagues advocates for the incorporation of molecular biomarkers for AD diagnosis in clinical practice. However, this approach only partially captures the complexity of disease expression due to co-pathologies such as limbic-predominant age-related TDP-43 encephalopathy, a mimic of AD. At the era of immunotherapy for AD, clinical expertise remains essential to identify AD from its mimics, especially when both entities co-exist, and may rely on advanced neuroimaging techniques such as brain connectivity.

Indexed as

Alzheimer DiseaseBiomarkersBrainNeuroimagingHumansBiomarkersage-related memory disordersAlzheimer's diseasebiomarkersfunctional magnetic resonance imaging

Identifiers

PMID40111924

DOI10.1177/13872877251328953

PMCPMC12932685

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.